Table 5.
Quality of life outcomes from the ATTAIN trial
| Abatacept (mean change from baseline) | Placebo (Mean change from baseline) | p (abatacept vs placebo) | |
|---|---|---|---|
| Physical function | 5.3 | 1.3 | <0.001 |
| Physical role | 6.5 | 1.3 | <0.001 |
| Pain | 8.7 | 2.5 | <0.001 |
| General health | 4.0 | 0.7 | <0.001 |
| Vitality | 6.6 | 1.8 | <0.001 |
| Social function | 7.3 | 2.4 | <0.001 |
| Emotional role | 6.0 | 2.5 | <0.05 |
| Mental health | 4.3 | 1.6 | <0.01 |
| Physical component summary | 6.6 | 1.1 | <0.001 |
| Mental component summary | 5.2 | 2.1 | <0.005 |
| PainVAS | −27.1 | −7.9 | <0.001 |
| FatigueVAS | −21.9 | −6.0 | <0.001 |
| MOS Sleep | |||
| Problems index | −9.4 | −2.8 | <0.001 |
| No. days unable to perform activities of daily living | −7.02 | −1.87 | <0.001 |
Note: For SF36 characteristics values represent mean decrease from baseline. A ≥3 point decrease would be regarded as clinically meaningful. For VAS, days unable to perform activites of daily living, and MOS Sleep problems index a negative value indicates an improvement.
Abbreviations: ATTAIN, Abatacept trial in treatment of anti-tumor necrosis factor inadequate responders; MOS, Sleep, Medical Outcomes Study Sleep Module; VAS visual analog scale.